A sequencing analysis in the neoadjuvant GeparSepto trial showed a significantly reduced pCR rate in PIK3CA-mutated breast cancer compared with PIK3CA wild-type breast cancer (23% vs. 38.8%, p < 0.0001)40. This evidence concerns the gene PIK3CA and breast carcinoma.